Clinical Trial Update: A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating LTX-315 in combination with GV1001 as an immunologic adjunct after curative surgery for carcinoma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma

Drugs mentioned

• GV1001
• LTX-315 (LTX-315 peptide)

Snippet

Sponsor: Lytix Biopharma AS | Conditions: Carcinoma | Phase 1 | Status: COMPLETED